After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. | The city scored its own ...
With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...
When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...
BMS ran its first C2C4C event in 2014, when an employee worked with colleagues to put together a team of 53 oncology staffers ...
Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...
Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks ...
Why is PDA’s Universe of Pre-Filled Syringes and Injection Devices Conference the must-attend event of the year? Get an ...
The Rybrevant-Lazcluze combo lowered the risk of death by 23% compared with Tagrisso in an updated analysis of the phase 3 ...
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...
Madrigal Pharmaceuticals broke new ground earlier this year as its Rezdiffra became the first drug approved by the FDA to ...
GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. On ...
Astellas is closing a gene therapy manufacturing facility in South San Francisco. But, across the country, the company opened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback